Iron Replacement Therapy Triferic AVNU Now Available
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Anemias
Canagliflozin May Reduce Anemia Risk in Diabetic CKD
In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.
FDA Requests Clarification of Data to Complete Roxadustat Review
The Agency announced that additional clarification of clinical data was needed prior to completing the review.
IV Iron Products: Adverse Events, Associated Costs Compared
The comparative study aimed to analyze AEs as well as estimate the associated medical costs for 4 IV iron preparations.
Pegcetacoplan Gets Priority Review for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that inhibits the complement cascade centrally at C3 and C3b.
Manufacturing Deficiencies Delay Decision on Sutimlimab for Cold Agglutinin Disease
Sutimlimab is an investigational monoclonal antibody designed to stop hemolysis by selectively inhibiting C1s in the classical complement pathway.
FDA Approves New Formulation of Ultomiris for PNH and aHUS
The FDA has approved a new 100mg/mL formulation of Ultomiris® (ravulizumab-cwvz; Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and pediatric patients.
Generic Version of Ferriprox Now Available
Deferiprone is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Factors Contributing to Darbepoetin Responsiveness in CKD
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Vadadustat Noninferior to Darbepoetin in CKD
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
